S. K. Chia, C. H. Speers, D. 'yachkova, Y. Kang, A. Malfair-taylor et al., The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer, Cancer, vol.110, issue.5, pp.973-982, 2007.

P. Mosconi, M. Colozza, D. Laurentiis, M. , D. Placido et al., Survival, quality of life and breast cancer, Ann Oncol, vol.12, issue.3, pp.15-24, 2001.

E. Andreopoulou and G. N. Hortobagyi, Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy, J Clin Oncol, vol.26, issue.22, pp.3660-3662, 2008.

R. Largillier, J. M. Ferrero, J. Doyen, J. Barriere, M. Namer et al., Prognostic factors in 1,038 women with metastatic breast cancer, Ann Oncol, vol.19, issue.12, pp.2012-2021, 2008.

D. J. Lobbezoo, R. J. Van-kampen, A. C. Voogd, M. W. Dercksen, F. Van-den-berkmortel et al., Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome, Breast Cancer Res Treat, vol.141, issue.3, pp.507-521, 2013.

E. F. Solomayer, I. J. Diel, G. C. Meyberg, C. Gollan, and G. Bastert, Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis, Breast Cancer Res Treat, vol.59, issue.3, pp.271-279, 2000.

S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant et al., Third consensus on medical treatment of metastatic breast cancer, Ann Oncol, vol.20, issue.11, pp.1771-1776, 2009.

A. C. Regierer, R. Wolters, M. P. Ufen, A. Weigel, I. Novopashenny et al., An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients, Ann Oncol, vol.25, issue.3, pp.633-641, 2014.

H. Kennecke, R. Yerushalmi, R. Woods, M. C. Cheang, D. Voduc et al., Metastatic behavior of breast cancer subtypes, J Clin Oncol, vol.28, issue.20, pp.3271-3278, 2010.

S. Dawood, K. Broglio, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review, J Clin Oncol, vol.28, issue.1, pp.92-100, 2010.

N. Yamamoto, T. Watanabe, N. Katsumata, Y. Omuro, M. Ando et al., Construction and validation of a practical prognostic index for patients with metastatic breast cancer, J Clin Oncol, vol.16, issue.7, pp.2401-2409, 1998.

L. Wyld, E. Gutteridge, S. E. Pinder, J. J. James, S. Y. Chan et al., Prognostic factors for patients with hepatic metastases from breast cancer, Br J Cancer, vol.89, issue.2, pp.284-90, 2003.
DOI : 10.1038/sj.bjc.6601038
URL : https://www.nature.com/articles/6601038.pdf

J. E. Brown, R. J. Cook, A. Lipton, and R. E. Coleman, Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients, Clin Cancer Res, vol.18, pp.6348-55, 2012.

F. C. Bidard, D. Hajage, T. Bachelot, S. Delaloge, E. Brain et al., Assessment of circulating tumor cells and serum markers for progressionfree survival prediction in metastatic breast cancer: a prospective observational study, Breast Cancer Res, vol.14, issue.1, p.29, 2012.

J. S. Lee, S. Park, J. M. Park, J. H. Cho, S. I. Kim et al., Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers, Breast Cancer Res Treat, vol.141, issue.3, pp.477-84, 2013.

Y. Shao, X. Sun, Y. He, C. Liu, and H. Liu, Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast Cancer, PLoS One, vol.10, issue.7, p.133830, 2015.

A. Darlix, P. J. Lamy, E. Lopez-crapez, A. L. Braccini, N. Firmin et al., Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients, BMC Cancer, vol.16, p.428, 2016.

C. Tsé, A. S. Gauchez, W. Jacot, and P. J. Lamy, HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer, Cancer Treat Rev, vol.38, issue.2, pp.133-175, 2012.

J. Baselga, J. Cortés, S. A. Im, C. E. Ross, G. Kiermaier et al., Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer, J Clin Oncol, vol.32, issue.33, pp.3753-61, 2014.

L. I. Binder, A. Frankfurter, and L. I. Rebhun, The distribution of tau in the mammalian central nervous system, J Cell Biol, vol.101, issue.4, pp.1371-1379, 1985.

G. V. Johnson, C. D. Bailey, and . Tau, where are we now?, J Alzheimers Dis, vol.4, pp.375-98, 2002.

R. Rouzier, R. Rajan, P. Wagner, K. R. Hess, D. L. Gold et al., Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer, Proc Natl Acad Sci, vol.102, issue.23, pp.8315-8335, 2005.

S. Souter and G. Lee, Microtubule-associated protein tau in human prostate cancer cells: isoforms, phosphorylation, and interactions, J Cell Biochem, vol.108, issue.3, pp.555-64, 2009.

M. T. Baquero, K. Lostritto, M. D. Gustavson, K. A. Bassi, F. Appia et al., Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts, Breast Cancer Res, vol.13, issue.5, p.85, 2011.

M. A. Matrone, R. A. Whipple, K. Thompson, E. H. Cho, M. I. Vitolo et al., Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells, Oncogene, vol.29, issue.22, pp.3217-3244, 2010.

C. Bonneau, Z. A. Gurard-levin, F. Andre, L. Pusztai, and R. R. Predictive, Prognostic value of the TauProtein in breast Cancer, Anticancer Res, vol.35, issue.10, pp.5179-84, 2015.

Y. Y. Shao, K. T. Kuo, F. C. Hu, Y. S. Lu, C. S. Huang et al., Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin, Jpn J Clin Oncol, vol.40, issue.4, pp.286-93, 2010.

T. Sunderland, G. Linker, and N. Mirza, Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, vol.289, pp.2094-103, 2003.

M. Riemenschneider, S. Wagenpfeil, and J. Diehl, Tau and Abeta42 protein in CSF of patients with frontotemporale degeneration, Neurology, vol.58, issue.11, pp.1622-1630, 2002.

H. Bartosik-psujek and J. J. Archelos, Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis ans correlate with intrathecal synthsis of IgG, J Neurol, vol.251, issue.4, pp.414-434, 2004.

C. Hesse, L. Rosengren, and E. Vanmechelen, Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke, J Alzheimers Dis, vol.2, issue.3-4, pp.199-206, 2000.

A. Bitsch and C. Horn, Kemmling yet al. Serum tau protein level as a marker of axonal damage in acute ischemic stroke, Eur Neurol, vol.47, issue.1, pp.45-51, 2002.

G. J. Shaw, E. C. Jauch, and F. P. Zemlan, Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury, Ann Emerg Med, vol.39, pp.254-261, 2002.

P. Shahim, K. Blennow, and H. Zetterberg, Tau, s-100 calcium-binding protein B, and neuron-specific enolase as biomarkers of concussion-reply, JAMA Neurol, vol.71, issue.7, pp.926-933, 2014.

O. Ahmad, J. Wardlaw, and W. N. Whiteley, Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review, Cerebrovasc Dis, vol.33, pp.47-54, 2012.

J. M. De-bont, H. Vanderstichele, and R. E. Reddingius, Increased total-tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients, Eur J Paediatr Neurol, vol.12, issue.4, pp.334-375, 2008.

S. W. Van-gool, E. Van-kerschaver, and P. Brock, Disease-and treatmentrelated elevation of the neurodegenerative marker tau in children with hematological malignancies, Leukemia, vol.14, issue.12, pp.2076-84, 2000.

A. Darlix, P. J. Lamy, E. Lopez-crapez, A. L. Braccini, N. Firmin et al., Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?, Int J Cancer, vol.139, issue.10, pp.2299-311, 2016.

. Darlix, BMC Cancer, vol.19, p.110, 2019.

D. M. Rissin, C. W. Kan, T. G. Campbell, S. C. Howes, D. R. Fournier et al., Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations, Nat Biotechnol, vol.28, issue.6, pp.595-604, 2010.

L. M. Mcshane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion et al., Statistics subcommittee of NCI-EORTC working group on Cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK), Breast Cancer Res Treat, vol.100, issue.2, pp.229-264, 2006.

E. L. Kaplan and P. Meier, Nonparametric estimation from incomplete observations, J Am Stat Assoc, vol.53, pp.457-81, 1958.

W. J. Youden, Index for rating diagnostic tests, Cancer, vol.3, pp.32-37, 1950.

I. M. Subbiah, X. Lei, J. S. Weinberg, E. P. Sulman, M. Chavez-macgregor et al., Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast Cancer and Brain metastases, J Clin Oncol, vol.33, issue.20, pp.2239-2284, 2015.

G. Griguolo, W. Jacot, E. Kantelhardt, M. V. Dieci, C. Bourgier et al., External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases: a multicentric European experience, Breast, vol.37, pp.36-41, 2017.

P. Cengiz, F. Zemlan, J. C. Eickhoff, R. Ellenbogen, and J. J. Zimmerman, Increased cerebrospinal fluid cleaved tau protein (C-tau) levels suggest axonal damage in pediatric patients with brain tumors, Childs Nerv Syst, vol.31, issue.8, pp.1313-1322, 2015.

M. T. Wunderlich, H. Lins, M. Skalej, C. W. Wallesch, and M. Goertler, Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke, Clin Neurol Neurosurg, vol.108, pp.558-63, 2006.

Y. Tsukada, A. Fouad, J. W. Pickren, and W. W. Lane, Central nervous system metastasis from breast carcinoma. Autopsy study, Cancer, vol.52, issue.12, pp.2349-54, 1983.

F. G. Davis, T. A. Dolecek, B. J. Mccarthy, and J. L. Villano, Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data, Neuro-Oncology, vol.14, issue.9, pp.1171-1178, 2012.